{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-112848","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.515918+00:00","generated_at":"2026-05-30T07:33:30.881836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicycle Therapeutics reports Q3 net loss $50.8M; strong cash $890.9M; 45% ORR for zelenectide pevedotin","bullets":["Net loss $50.8M ($0.74/shr) in Q3 2024 vs $49.9M ($1.26/shr) in Q3 2023; R&D spend $48.3M, up from $39.9M.","Cash $890.9M as of Sep 30, 2024, up from $526.4M at Dec 31, 2023; expects cash runway into 2H 2027; $31.7M UK tax credit received Oct 2024.","Zelenectide pevedotin (Nectin-4 BTC) monotherapy: 45% ORR in mUC (n=38), median DOR 11.1 months; differentiated safety profile; Phase 2/3 Duravelo-2 enrolling.","BT5528 (EphA2 BTC) monotherapy: 45% ORR in mUC at 6.5 mg/m2 Q2W (n=11); low peripheral neuropathy rates; combo with nivolumab expected 2025.","First human imaging data for BRC targeting MT1-MMP validates target; selected EphA2 as second BRC target; signed LOI with Eckert & Ziegler."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-112848","json":"https://secwatch.observer/filing/0001104659-24-112848.json","markdown":"https://secwatch.observer/filing/0001104659-24-112848.md","text":"https://secwatch.observer/filing/0001104659-24-112848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924112848/0001104659-24-112848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924112848/tm2426652d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:33:30.881836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}